SCHEMBL3200799

SCHEMBL3200799

CCOC(=O)c1cc(F)cc(-c2ccc(F)c3cc(CBr)sc23)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 1/20 0.38
NPC1 O15118 3/20 0.35
MAPT P10636 3/20 0.35
RAB9A P51151 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KDM4E B2RXH2 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
PRF1 P14222 1/20 0.35
ALOX5 P09917 2/20 0.34
MAPK14 Q16539 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1855839 0.96 GPR52 (0.36) GPR52NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL1851614 0.91 GPR52 (0.38) GPR52NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL1859911 0.90 GPR52 (0.46) GPR52NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL1852550 0.88 GPR52 (0.46) GPR52NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL1850115 0.86 GPR52 (0.44) GPR52NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL1851317 0.85 GPR52 (0.43) GPR52NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL1849690 0.84 GPR52 (0.49) GPR52NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL1851411 0.83 NPC1 (0.37) GPR52NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL1851460 0.81 GPR52 (0.61) GPR52MAPTHPGDALDH1A1
SCHEMBL1864780 0.81 GPR52 (0.50) GPR52NPC1MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885NPC1 2479/4885MAPT 4174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.